There are currently 58 active clinical trials seeking participants for Rheumatoid Arthritis research studies. The states with the highest number of trials for Autism participants are Florida, California, Texas and Pennsylvania.
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
NCT05814627
Recruiting
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is doubl... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona +178 locations
Conditions: Rheumatoid Arthritis
Register for Updates
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis
NCT06073093
Recruiting
This is a parallel group, Phase 2, randomized, double-blind, placebo controlled, 5-arm, international, multicenter, 12-week proof of concept, dose finding study. It is designed to assess efficacy and safety of treatment with SAR441566 for 12 weeks. It will be conducted in male and female adult participants with moderate-to-severe rheumatoid arthritis (RA) not adequately controlled on methotrexate (MTX) and biologic/targeted synthetic disease modifying anti-rheumatic drug (DMARD) naive. Study tr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/11/2024
Locations: Inland Rheumatology Clinical Trials, Inc. Site Number : 8400004, Upland, California +41 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
NCT03816345
Recruiting
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/06/2024
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +50 locations
Conditions: Autoimmune Disease, Crohn Disease, Dermatomyositis, Inflammatory Bowel Disease, Multiple Sclerosis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis, Hematopoietic and Lymphoid Cell Neoplasm, Psoriasis, Psoriatic Arthritis, Malignant Solid Neoplasm
Register for Updates
A Study of Baricitinib in Participants With Rheumatoid Arthritis
NCT04086745
Recruiting
This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis (RA).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/05/2024
Locations: Arizona Arthritis & Rheumatology Associates, Flagstaff, Arizona +88 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Study of GS-0272 in Participants With Rheumatoid Arthritis or Systemic Lupus Erythematosus
NCT06031415
Recruiting
The goals of this clinical study are to learn more about the study drug, GS-0272, and its safety and tolerability following multiple doses in participants with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). The primary objectives of this study are to assess the safety and tolerability of multiple ascending subcutaneous (SC) doses of GS-0272 and to characterize the pharmacokinetics of GS-0272 following multiple SC doses of GS-0272, in participants with RA or SLE.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/05/2024
Locations: Clinical Research of West Florida, Inc., Clearwater, Florida +4 locations
Conditions: Rheumatoid Arthritis, Systemic Lupus Erythematosus
Register for Updates
A Phase 1b Study of Imvotamab in Moderate to Severe Rheumatoid Arthritis
NCT06087406
Recruiting
The purpose of this study is to determine the safety and tolerability of imvotamab in patients with moderate to severe rheumatoid arthritis who have failed prior therapies. Participants will be given imvotamab or placebo through a vein (i.e., intravenously). A placebo is a look-alike substance that contains no active drug
Gender:
All
Ages:
18 years and above
Trial Updated:
03/29/2024
Locations: Anniston Medical Clinic, Anniston, Alabama +15 locations
Conditions: Rheumatoid Arthritis, Arthritis, Rheumatoid, Arthritis
Register for Updates
Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis
NCT03912428
Recruiting
Background: Inflammation can play a role in diseases like heart disease and rheumatoid arthritis. PET scans can help detect inflammation. Two new drugs may create better PET images. Objective: To see if the drugs [11C]ER176 and [11C]MC1 can help image inflammation. Eligibility: People ages 18 and older with rheumatoid arthritis or idiopathic inflammatory myopathy (IIM). Healthy volunteers enrolled in protocol 01-M-0254 or 17-M-0181 are also needed. Design: Healthy participants will be sc... Read More
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/28/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Myositis, Inflammatory, Rheumatoid Arthritis, Healthy Volunteers
Register for Updates
Actis Total Hip System 2 Year Follow-up
NCT02783274
Recruiting
Two-year (2 year) information regarding the performance of the commercially available Actis™ Total Hip System in order to obtain and evaluate the clinical outcomes on a series of cementless primary total hip arthroplasty (THA) and hemi-hip arthroplasty procedures using clinical, radiographic and device and procedure related adverse event assessments.
Gender:
All
Ages:
21 years and above
Trial Updated:
03/26/2024
Locations: Not set, Louisville, Kentucky +9 locations
Conditions: Osteoarthritis, Traumatic Arthritis, Rheumatoid Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of the Femoral Head, Acute Traumatic Fracture of the Femoral Head or Neck, Certain Cases of Ankylosis, Non-union of Femoral Neck Fractures, Certain High Sub-Capital & Femoral Neck Fractures in Elderly
Register for Updates
Rheumatology Diet Study
NCT06339957
Recruiting
This study aims to collect information on rheumatology patients' dietary habits, autoimmune disease activity, dietary changes, disease symptom improvements, and perceptions on their dietary habits and how it affects their autoimmune disease. The main objective is to see if rheumatology patients change their dietary habits after their diagnosis of an autoimmune disease and if it subjectively improved their disease symptoms. It will also look at rheumatology patients' expectations for their rheuma... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/25/2024
Locations: UCF Health Clinics, Orlando, Florida
Conditions: Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Dermatomyositis/Polymyositis, Sjogren's Syndrome, Systemic Lupus Erythematous, Scleroderma, Fibromyalgia
Register for Updates
Study of Single Doses of SBT777101 in Subjects With Rheumatoid Arthritis
NCT06201416
Recruiting
This study will test the safety and effects of SBT777101 when given as a single dose to subjects with rheumatoid arthritis. It is the first study of this treatment being done in humans. Increasing dose levels will be given after the safety at lower dose levels is shown.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/21/2024
Locations: Mayo Clinic, Scottsdale, Arizona +4 locations
Conditions: Rheumatoid Arthritis
Register for Updates
Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis
NCT05782335
Recruiting
The condition that will be studied is Rheumatoid Arthritis (RA), and in particular, RA patients with moderate to highly active disease who were prescribed Abatacept (Orencia®) (ABA) by their physician during their setting of care at Hospital for Special Surgery (HSS). This investigator-initiated, prospective, comparative, 3-arm observational study will examine changes in lymphocytes in RA patients starting abatacept compared to RA patients starting TNF inhibitors and to healthy controls. This wi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/13/2024
Locations: Hospital for Special Surgery, New York, New York
Conditions: Rheumatoid Arthritis
Register for Updates
RA-PRO PRAGMATIC TRIAL
NCT04692493
Recruiting
The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: East Alabama Arthritis Center PC, Auburn, Alabama +48 locations
Conditions: Rheumatoid Arthritis
Register for Updates